ArticleKidney medicine2025
Collapsing Glomerulopathy in a Patient With Myelodysplastic Syndrome With Isolated del(5q): A Case Report.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotic syndrome associated with myelodysplastic syndromes (MDSs) is rare, and collapsing glomerulopathy (CG) in this condition is extremely uncommon. We report a case of CG in a 62-year-old man who presented with generalized edema, severe anemia, acute kidney injury, and nephrotic-range proteinuria. Laboratory tests showed hypoalbuminemia and elevated serum creatinine, whereas kidney ultrasound showed normal-sized kidneys with increased parenchymal echogenicity. Kidney biopsy confirmed a diagnosis of CG, and subsequent bone marrow biopsy showed myelodysplastic syndromes with isolated 5q deletion (MDS-del(5q)) and low blast count. The patient was treated with oxymetholone, erythropoietin, and lenalidomide. Despite treatment, his kidney function deteriorated, leading to kidney failure with replacement therapy. To our knowledge, CG is a rare cause of nephrotic syndrome in patients with MDS, particularly in those with MDS-del(5q), and has not been previously reported. This case underscores the importance of considering hematologic malignancies, including MDS, in the differential diagnosis of CG, especially when accompanied by cytopenias. Early recognition of the underlying etiology is essential for guiding treatment and may offer the opportunity to modify disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.